Disclaimer to the On-line Edition
This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.



  • the treatment of suspected or documented bacterial infections, normally caused by Gram-negative organisms.


  • tobramycin is an aminoglycoside antibiotic
  • aminoglycosides, which are generally bactericidal, are believed to act by irreversibly binding to 30S ribosomal subunits, thereby inhibiting protein synthesis
  • aminoglycosides are active against many aerobic Gram-negative bacteria and some Gram-positive bacteria; their clinical application is usually reserved for Gram-negative organisms
  • aminoglycosides are inactive against fungi, viruses and most anaerobic bacteria
  • the average serum half life of tobramycin in neonates (< 1 week) varies between 3 and 12 hours; the half life is inversely correlated to birth weight and gestational age
  • tobramycin may have better antibacterial activity than gentamicin against Pseudomonas sp.

Side Effects

  • 8th nerve damage, deafness, ataxia, vestibulitis and renal failure
  • these effects are somewhat dose related, ie. the higher the dose, the greater potential for toxicity


  • never inject into a closed space (eg. pleural space or peritoneal cavity) in the neonate because there have been some reported incidences of sudden respiratory arrest in association with the injection
  • tobramycin may cause renal damage; therefore, accurate in and outs should be done; monitor serum creatinine
  • take peak values 30 minutes after the end of the 30 minute infusion (should be 13 - 22.0 micromol/L)
  • take trough values immediately before the next dose (should be less than 1.0 - 3.0 micromol/L)
  • levels should initially be monitored before and after the third dose
  • 0.25 mL of blood is required for the assay

Drug Interactions

  • furosemide and ethacrynic acid - increase ototoxicity
  • ticarcillin inactivates tobramycin if mixed together in vitro
  • carbenicillin - same as ticarcillin
  • cephalosporins - increased nephrotoxicity
  • skeletal muscle relaxants - (eg. pancuronium) tobramycin may potentiate muscle relaxation
  • vancomycin - concurrent use may increases the risk of ototoxicity. Although it is generally not recommended, if this combination is used, then monitor serum levels of both drugs, and renal function, closely.


  1. The following guidelines are for the FIRST WEEK OF LIFE.
    > 35 weeks 3.5 mg/kg q24h

    < 35 weeks

    3 mg/kg q24h

    • pre and post levels with 3rd dose
    • given IV by slow infusion
    • in overwhelming infection a loading dose of 4 mg/kg may be given, followed by the maintenance dosage regimen. If a loading dose is given, it is especially important to closely follow serum tobramycin levels

  2. AFTER THE FIRST WEEK OF LIFE, a larger dose (3.5 mg/kg) with the frequency based on postconceptional age, may be appropriate.
    < 26 weeks q24h
    27-32 weeks q18h

    > 32 weeks




  • 10 mg/mL, 2mL vial
  • 10 mg/mL syringe, prepared by Pharmacy


  1. McEvoy G K (ed): AHFS Drug Information, American Society of Hospital Pharmacists, 1991.
  2. Roberts, RJ: Drug Therapy in Infants, W.B. Saunders, Toronto, 1984.
  3. Watterberg KL, Kelly HW, Angelus P and Backstrom C: The need for a loading dose of gentamicin in neonates, Ther Drug Monitor 1989; 11:16-20.
  4. Bloome MR, Warren AJ, Ringer L and Walker PC: Evaluation of an empirical dosing schedule for gentamicin in neonates, Drug Intelligence and Clinical Pharmacy 1988; 22: 618-622.
  5. Taketomo CK, Hodding JH and Kraus DM: Pediatric Dosage Handbook, Lexi-Comp Inc., Cleveland, 1992.




Last Uploaded: Thursday, 26-May-2011 00:53:48 EDT